Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation
Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
Lymphoma Recent News
Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting
TG Therapeutics Shares Plunge After FDA Plans AdComm Meet For Blood Cancer Candidate
Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose
Soligenix To File US Application For Its Lymphoma Photodynamic Therapy In 2H 2022
Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting
BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate
ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty
Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response
Cellectar Receives $2M NIH Grant For Rare Lymphoma Study
F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients
BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma
Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21
Precision BioSciences' CD-19 CAR T Therapy Shows Response Rate Of 77% In Lymphoma Trial
BeiGene's Brukinsa US Application For Expanded Use Under FDA Review
Soligenix Stock Plummets After It Announces Not To Pursue Rolling US Application Submission For HyBryte
ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment
Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity
IMV's Lead Candidate To Be Evaluated With Keytruda In Pretreated B-Cell Lymphoma Patients
Affimed To Continue Enrollment In AFM13 Lymphoma Study After Positive Interim Data
BeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review
Miragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst
Here's Why Seattle Genetics' Adcetris Is A $2 Billion Product